Sugi Predict

Sugi Predict / Compounds / SCHEMBL7928560

SCHEMBL7928560

SCHEMBL7928560

CNC(=O)/C=C/CN(C)C

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CHRNB2 P17787 1/20 0.55
▸ CHRNB4 P30926 1/20 0.55
▸ CHRNA3 P32297 1/20 0.55
▸ CHRNA4 P43681 1/20 0.55
▸ JAK3 P52333 2/20 0.33
▸ EGFR P00533 5/20 0.32
▸ ITK Q08881 4/20 0.32
▸ BTK Q06187 3/20 0.32
▸ CDK14 O94921 2/20 0.32
▸ CCNY Q8ND76 2/20 0.32
▸ ERBB2 P04626 2/20 0.32
▸ NLRP3 Q96P20 1/20 0.31
▸ PIP4K2A P48426 1/20 0.30
▸ PIP4K2B P78356 1/20 0.30
▸ ACKR3 P25106 1/20 0.30
▸ KDR P35968 1/20 0.30
▸ HDAC3 O15379 1/20 0.30
▸ HDAC6 Q9UBN7 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20425354 1.00 CHRNB2 (0.55) CHRNB2CHRNB4CHRNA3CHRNA4JAK3
SCHEMBL27451892 1.00 CHRNB2 (0.55) CHRNB2CHRNB4CHRNA3CHRNA4JAK3
Propionamide SCHEMBL28134813 0.89 CHRNB2 (0.46) CHRNB2CHRNB4CHRNA3CHRNA4JAK3
SCHEMBL18687355 0.83 CHRNB2 (0.41) CHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL27295714 0.83 CHRNB2 (0.39) CHRNB2CHRNB4CHRNA3CHRNA4JAK3
SCHEMBL15829888 0.82 CHRNB2 (0.47) CHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL23653179 0.81 CHRNB2 (0.38) CHRNB2CHRNB4CHRNA3CHRNA4JAK3
SCHEMBL17120398 0.81 CHRNB2 (0.50) CHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL31335959 0.81 CHRNB2 (0.50) CHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL16665104 0.80 CHRNB2 (0.36) CHRNB2CHRNB4CHRNA3CHRNA4JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 215 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024129395-A1 BTK INHIBITORS GWYNANT THERAPEUTICS, INC. (US) 2024-06-20 — — WO disclosed
EP-4006035-B1 QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER NEUPHARMA INC (US) 2023-11-22 — — EP disclosed
EP-4279486-A1 2-AMINOPYRIMIDINE COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF AND APPLICATION THEREOF Guangzhou Salustier Biosciences Co., Ltd. (CN) 2023-11-22 — — EP disclosed
EP-3350181-B1 HER3 LIGANDS AND USES THEREOF UNIV CALIFORNIA (US) 2023-11-01 — — EP disclosed
US-20230339922-A1 COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF DANA FARBER CANCER INST INC (US) 2023-10-26 — — US disclosed
US-20230339922-A1 COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF DANA FARBER CANCER INST INC (US) 2023-10-26 — — US disclosed
US-20230303586-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2023-09-28 — — US disclosed
US-20230286904-A1 INHIBITORS OF YAP/TAZ-TEAD ONCOPROTEINS, SYNTHESIS AND USE THEREOF BRIDGENE BIOSCIENCES, INC. 2023-09-14 — — US disclosed
US-20230286904-A1 INHIBITORS OF YAP/TAZ-TEAD ONCOPROTEINS, SYNTHESIS AND USE THEREOF BRIDGENE BIOSCIENCES, INC. 2023-09-14 — — US disclosed
US-20230271938-A1 BENZIMIDAZOLES FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES CAPELLA THERAPEUTICS, INC. 2023-08-31 — — US disclosed
US-20080200433-A1 Molecular Chaperone Function Regulator MITSUBISHI TANABE PHARMA CORPORATION (JP) 2008-08-21 — — US disclosed
US-20080200433-A1 Molecular Chaperone Function Regulator MITSUBISHI TANABE PHARMA CORPORATION (JP) 2008-08-21 — — US disclosed
EP-1939625-A2 Methods for ligand discovery Sunesis Pharmaceuticals, Inc. (US) 2008-07-02 — — EP disclosed
US-20070265260-A1 Quinazoline derivatives MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-11-15 — — US disclosed
US-20070265260-A1 Quinazoline derivatives MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-11-15 — — US disclosed
US-7294629-B2 Quinazoline derivatives MITSUBISHI PHARMA CORPORATION (JP) 2007-11-13 — — US disclosed
US-7294629-B2 Quinazoline derivatives MITSUBISHI PHARMA CORPORATION (JP) 2007-11-13 — — US disclosed
US-7214487-B2 Methods for identifying compounds that modulate enzymatic activities by employing covalently bonded target-extender complexes with ligand candidates SUNESIS PHARMACEUTICALS, INC. (US) 2007-05-08 — — US disclosed
US-7202033-B2 Identification of kinase inhibitors SUNESIS PHARMACEUTICALS, INC. (US) 2007-04-10 — — US disclosed
US-7202033-B2 Identification of kinase inhibitors SUNESIS PHARMACEUTICALS, INC. (US) 2007-04-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230286904-A1 INHIBITORS OF YAP/TAZ-TEAD ONCOPROTEINS, SYNTHESIS AND USE THEREOF TEAD1, TEAD2, TEAD3 CHRNB2 4563/4885CHRNB4 4496/4885CHRNA3 4647/4885
US-20230339922-A1 COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF EGFR, ERBB2, ERBB3 CHRNB2 4357/4885CHRNB4 4514/4885CHRNA3 4548/4885
US-20230303586-A1 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS CHRNB2 4246/4885CHRNB4 4398/4885CHRNA3 4602/4885
US-20230271938-A1 BENZIMIDAZOLES FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES CHKB, CHKA, CHUK CHRNB2 4817/4885CHRNB4 4859/4885CHRNA3 4771/4885
US-20070265260-A1 Quinazoline derivatives TYK2, ROR1, JAK1 CHRNB2 4861/4885CHRNB4 4819/4885CHRNA3 4667/4885
US-20080200433-A1 Molecular Chaperone Function Regulator HSPBP1, HSF1, HSPH1 CHRNB2 4466/4885CHRNB4 4230/4885CHRNA3 4333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.